Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Thierry André(Sorbonne Université)
Cited by 872
Related Papers
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Immunotherapy in colorectal cancer: rationale, challenges and potential
|Nature Reviews Gastroenterology & Hepatology|2019|2k
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
|The Oncologist|2016|276